| Nonviral delivery of synthetic siRNAs in vivo S Akhtar, IF Benter The Journal of clinical investigation 117 (12), 3623-3632, 2007 | 645 | 2007 |
| Biosynthetic polyhydroxyalkanoates and their potential in drug delivery CW Pouton, S Akhtar Advanced Drug Delivery Reviews 18 (2), 133-162, 1996 | 543 | 1996 |
| Cellular uptake and intracellular fate of antisense oligonucleotides. S Akhtar, RL Juliano Trends in Cell Biology 5 (2), 139-144, 1992 | 383* | 1992 |
| The delivery of antisense therapeutics S Akhtar, MD Hughes, A Khan, M Bibby, M Hussain, Q Nawaz, J Double, ... Advanced drug delivery reviews 44 (1), 3-21, 2000 | 346 | 2000 |
| Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity S Akhtar, I Benter Advanced drug delivery reviews 59 (2-3), 164-182, 2007 | 310 | 2007 |
| In vivo studies with antisense oligonucleotides S Akhtar, S Agrawal Trends in Pharmacological Sciences 18 (1), 12-18, 1997 | 271 | 1997 |
| Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera S Akhtar, R Kole, RL Juliano Life Sciences 49 (24), 1793-1801, 1991 | 271 | 1991 |
| Mechansism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages Y Shoji, S Akhtar, A Periasamy, B Herman, RL Juliano Nucleic acids research 19 (20), 5543-5550, 1991 | 247 | 1991 |
| Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies A Khan, M Benboubetra, PZ Sayyed, K Wooi Ng, S Fox, G Beck, IF Benter, ... Journal of drug targeting 12 (6), 393-404, 2004 | 207 | 2004 |
| Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes) S Akhtar, S Basu, E Wickstrom, RL Juliano Nucleic acids research 19 (20), 5551-5559, 1991 | 205 | 1991 |
| Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin-and oligofectamine-induced gene expression changes in human epithelial cells Y Omidi, AJ Hollins, M Benboubetra, R Drayton, IF Benter, S Akhtar Journal of drug targeting 11 (6), 311-323, 2003 | 191 | 2003 |
| Angiotensin‐(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2‐and NF‐κB‐dependent pathways AZ El‐Hashim, WM Renno, R Raghupathy, HT Abduo, S Akhtar, IF Benter British journal of pharmacology 166 (6), 1964-1976, 2012 | 189 | 2012 |
| Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors S Akhtar, J McSwiggen US Patent App. 09/916,466, 2003 | 174 | 2003 |
| Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type Y Omidi, AJ Hollins, RM Drayton, S Akhtar Journal of drug targeting 13 (7), 431-443, 2005 | 172 | 2005 |
| The cellular delivery of antisense oligonucleotides and ribozymes MD Hughes, M Hussain, Q Nawaz, P Sayyed, S Akhtar Drug discovery today 6 (6), 303-315, 2001 | 150 | 2001 |
| Delivery strategies for siRNA-mediated gene silencing IR Gilmore, SP Fox, AJ Hollins, S Akhtar Current drug delivery 3 (2), 147-155, 2006 | 148 | 2006 |
| Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity AJ Hollins, Y Omidi, IF Benter, S Akhtar Journal of drug targeting 15 (1), 83-88, 2007 | 136 | 2007 |
| Liposomes as a drug delivery system for antisense oligonucleotides RL Juliano, S Akhtar Antisense research and development 2 (2), 165-176, 1992 | 134 | 1992 |
| Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer FS Cyprian, S Akhtar, Z Gatalica, S Vranic Bosnian Journal of Basic Medical Sciences 19 (3), 227, 2019 | 124 | 2019 |
| The design and exogenous delivery of siRNA for post-transcriptional gene silencing IR Gilmore, SP Fox, AJ Hollins, M Sohail, S Akhtar Journal of drug targeting 12 (6), 315-340, 2004 | 118 | 2004 |